Prostate Cancer Nomograms and Their Application in Asian Men: a Review

Overview

Journal Prostate Int

Date 2024 Mar 25

PMID 38523898

Authors

Sridhar Panaiyadiyan

Rajeev Kumar

Affiliations

Soon will be listed here.

Abstract

Nomograms help to predict outcomes in individual patients rather than whole populations and are an important part of evaluation and treatment decision making. Various nomograms have been developed in malignancies to predict and prognosticate clinical outcomes such as severity of disease, overall survival, and recurrence-free survival. In prostate cancer, nomograms were developed for determining need for biopsy, disease course, need for adjuvant therapy, and outcomes. Most of these predictive nomograms were based on Caucasian populations. Prostate cancer is significantly affected by race, and Asian men have a significantly different racial and genetic susceptibility compared to Caucasians, raising the concern in generalizability of these nomograms. We reviewed the existing literature for nomograms in prostate cancer and their application in Asian men. There are very few studies that have evaluated the applicability and validity of the existing nomograms in these men. Most have found significant differences in the performance in this population. Thus, more studies evaluating the existing nomograms in Asian men or suggesting modifications for this population are required.

Citing Articles

Harnessing machine learning to predict prostate cancer survival: a review.

Bang S, Ahn Y, Koo K Front Oncol. 2025; 14:1502629.

PMID: 39868377 PMC: 11757104. DOI: 10.3389/fonc.2024.1502629.

A prognostic nomogram of non-small cell lung cancer based on tumor marker inflammatory nutrition score.

Feng Y, Qiao H, Han X, Tang H Transl Lung Cancer Res. 2025; 13(12):3392-3406.

PMID: 39830779 PMC: 11736597. DOI: 10.21037/tlcr-24-708.

Hematospermia does not increase the risk of prostate cancer detection in prostate biopsy.

Park J, Paick S, Choi W, Kim A, Kim H, Chung B Prostate Int. 2025; 12(3):151-154.

PMID: 39816940 PMC: 11733752. DOI: 10.1016/j.prnil.2024.06.004.

Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer.

Morizane S, Takenaka A Prostate Int. 2025; 12(3):117-127.

PMID: 39816936 PMC: 11733762. DOI: 10.1016/j.prnil.2024.03.002.

The impact of obesity and sexual behavior on prostate cancer risk is mediated by testosterone levels: a mendelian randomization study and mediation analysis.

Di H, Wen Y, Wang J, Wang J, Wang Y, Li Y Prostate Int. 2024; 12(2):96-103.

PMID: 39036754 PMC: 11255935. DOI: 10.1016/j.prnil.2024.03.003.

References

Smaletz O, Scher H, Small E, Verbel D, McMillan A, Regan K . Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20(19):3972-82. DOI: 10.1200/JCO.2002.11.021. View

Kattan M, Zelefsky M, Kupelian P, Cho D, Scardino P, Fuks Z . Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003; 21(24):4568-71. DOI: 10.1200/JCO.2003.05.046. View

Clarke M, Kennedy K, MacDonagh R . Development of a clinical prediction model to calculate patient life expectancy: the measure of actuarial life expectancy (MALE). Med Decis Making. 2008; 29(2):239-46. DOI: 10.1177/0272989X08327114. View

Tang P, Chen H, Uhlman M, Lin Y, Deng X, Wang B . A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl. 2013; 15(1):129-33. PMC: 3739110. DOI: 10.1038/aja.2012.111. View

Yoon D, Park J, Yoon S, Park M, Moon D, Lee J . Can the prostate risk calculator based on Western population be applied to Asian population?. Prostate. 2011; 72(7):721-9. DOI: 10.1002/pros.21475. View

Baccala Jr A, Reuther A, Bianco Jr F, Scardino P, Kattan M, Klein E . Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients. Urology. 2007; 69(3):536-40. DOI: 10.1016/j.urology.2006.12.013. View

RAGDE H, Elgamal A, Snow P, Brandt J, Bartolucci A, Nadir B . Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998; 83(5):989-1001. DOI: 10.1002/(sici)1097-0142(19980901)83:5<989::aid-cncr26>3.0.co;2-q. View

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

Smith B, Smith G, Hurria A, Hortobagyi G, Buchholz T . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-65. DOI: 10.1200/JCO.2008.20.8983. View

10.

Wang L, Hricak H, Kattan M, Schwartz L, Eberhardt S, Chen H . Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol. 2006; 186(3):743-8. DOI: 10.2214/AJR.04.1682. View

11.

Eastham J, May R, Robertson J, Sartor O, Kattan M . Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999; 54(4):709-13. DOI: 10.1016/s0090-4295(99)00213-7. View

12.

Steuber T, Graefen M, Haese A, Erbersdobler A, Chun F, Schlom T . Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006; 175(3 Pt 1):939-44. DOI: 10.1016/S0022-5347(05)00342-3. View

13.

Bluestein D, Bostwick D, Bergstralh E, Oesterling J . Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol. 1994; 151(5):1315-20. DOI: 10.1016/s0022-5347(17)35239-4. View

14.

Cooperberg M, Pasta D, Elkin E, Litwin M, Latini D, Du Chane J . The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173(6):1938-42. PMC: 2948569. DOI: 10.1097/01.ju.0000158155.33890.e7. View

15.

Kobayashi M, Kijima T, Yashi M, Kamai T . Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels. Prostate Int. 2023; 11(1):27-33. PMC: 9995685. DOI: 10.1016/j.prnil.2022.08.001. View

16.

Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J . Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18):1445-51. View

17.

Chun F, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V . Development and external validation of an extended 10-core biopsy nomogram. Eur Urol. 2006; 52(2):436-44. DOI: 10.1016/j.eururo.2006.08.039. View

18.

Ackerman D, Barry J, Wicklund R, Olson N, Lowe B . Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 1993; 150(6):1845-50. DOI: 10.1016/s0022-5347(17)35912-8. View

19.

Partin A, Yoo J, Carter H, Pearson J, Chan D, Epstein J . The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150(1):110-4. DOI: 10.1016/s0022-5347(17)35410-1. View

20.

Kattan M, Zelefsky M, Kupelian P, Scardino P, Fuks Z, Leibel S . Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000; 18(19):3352-9. DOI: 10.1200/JCO.2000.18.19.3352. View